$ANIP

Ocular Therapeutix (OCUL) and ANI Pharmaceuticals (ANIP) stocks fell 6.7% and 4.3%, respectively, as healthcare sector sentiment weakened due to CMS canceling Affordable Care Act coverage for 760,000 people and clawing back $2.2B in subsidies. OCUL is down 13.8% YTD and 36.7% from its 52-week high.

ANI Pharmaceuticals (ANIP) received FDA approval for its generic Everolimus Tablets for Oral Suspension in 2mg, 3mg, and 5mg strengths. The product, a generic version of Afinitor Disperz, expands ANI's generics portfolio. The company expects to launch at least 15 new generic products this year. U.S. annual sales for the approved product were approximately $123 million, according to IQVIA data cited by ANI. ANIP's stock closed at $77.91 on Tuesday, with pre-market trading at $78.99.

ANI Pharmaceuticals (ANIP) appointed Henry Gosebruch to its board, replacing Muthusamy Shanmugam, who will remain in operational roles. Gosebruch has biotech leadership experience. The company, with a $1.6b market cap, develops and markets branded and generic drugs. Board changes may influence capital allocation and product mix.

ANI Pharmaceuticals Inc. (ANIP) filed an Initial Statement of Beneficial Ownership (Form 3) on August 19, 2026, disclosing a director's ownership of securities. The company is a diversified biopharmaceutical firm focused on rare disease treatments and generic pharmaceuticals, with segments including Rare Disease, Brands, and Generics.

ANI PHARMACEUTICALS INC (ANIP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors – Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., August 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Compa

ANI Pharmaceuticals (ANIP) reported Q2 and first-half 2026 results, reaffirming its net revenue outlook. The stock is down 0.90% in one day and 6.53% over 90 days, but up 176.54% over 5 years. The company is trading at $77.32, below a fair value estimate of $112.71, with growth potential in Cortrophin Gel and other rare disease products.

ANI Pharmaceuticals (ANIP) reported Q2 2026 earnings with total revenue of $266.0 million, up 25.9% YoY, driven by Rare Disease and Generics segments. Adjusted EBITDA rose 32.4% to $71.6 million, exceeding expectations. Cortrophin Gel revenue increased 43.5% to $117.1 million. The company reaffirmed full-year revenue guidance of $1.08B-$1.14B but lowered Cortrophin Gel outlook to $520M-$540M. Management highlighted progress in rare disease focus and sales force expansion.

A peer comparison of Q2 results in generic pharmaceuticals says the four tracked companies beat analysts’ revenue consensus by 2.6% on average, but shares fell 5.6% since reporting. ANI Pharmaceuticals (ANIP) revenue was $266m (+25.9%), EPS beat, but full-year revenue guidance missed; stock down 9.1% to $75.12. Amphastar (AMPH) revenue $183.9m (+5.4%) beat; stock up 2.3% to $20.28. Viatris (VTRS) revenue $3.76b (+4.9%) beat; stock down 7.6% to $16.32. Amneal (AMRX) revenue $796.2m (+9.9%) beat;

ANI Pharmaceuticals reported Q2 2026 sales of $266.04 million and net income of $24.71 million, and reaffirmed full-year 2026 net revenue guidance of $1.08 billion to $1.14 billion, according to the company. The article links results to rare disease therapy Cortrophin Gel and the generics portfolio.

ANI Pharmaceuticals (ANIP) trades at 7.6x forward 12-month EPS versus higher peers and market benchmarks. Zacks consensus projects 2026 revenue of $1.10B (+24.6%) and EPS of $9.40 (+19.1%). Cortrophin guidance was cut to $520-$540M, making it about 48% of revenue at midpoints, raising execution risk.